Literature DB >> 32009391

Ligand Conformational Bias Drives Enantioselective Modification of a Surface-Exposed Lysine on Hsp90.

Adolfo Cuesta1, Xiaobo Wan1,2, Alma L Burlingame2, Jack Taunton1.   

Abstract

Targeted covalent modification of surface-exposed lysines is challenging due to their low intrinsic reactivity and high prevalence throughout the proteome. Strategies for optimizing the rate of covalent bond formation by a reversibly bound inhibitor (kinact) typically involve increasing the reactivity of the electrophile, which increases the risk of off-target modification. Here, we employ an alternative approach for increasing kinact of a lysine-targeted covalent Hsp90 inhibitor, independent of the reversible binding affinity (Ki) or the intrinsic electrophilicity. Starting with a noncovalent ligand, we appended a chiral, conformationally constrained linker, which orients an arylsulfonyl fluoride to react rapidly and enantioselectively with Lys58 on the surface of Hsp90. Biochemical experiments and high-resolution crystal structures of covalent and noncovalent ligand/Hsp90 complexes provide mechanistic insights into the role of ligand conformation in the observed enantioselectivity. Finally, we demonstrate selective covalent targeting of cellular Hsp90, which results in a prolonged heat shock response despite concomitant degradation of the covalent ligand/Hsp90 complex. Our work highlights the potential of engineering ligand conformational constraints to dramatically accelerate covalent modification of a distal, poorly nucleophilic lysine on the surface of a protein target.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32009391     DOI: 10.1021/jacs.9b09684

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  8 in total

1.  Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking.

Authors:  Xiaobo Wan; Tangpo Yang; Adolfo Cuesta; Xiaming Pang; Trent E Balius; John J Irwin; Brian K Shoichet; Jack Taunton
Journal:  J Am Chem Soc       Date:  2020-03-04       Impact factor: 15.419

2.  Reversible lysine-targeted probes reveal residence time-based kinase selectivity.

Authors:  Tangpo Yang; Adolfo Cuesta; Xiaobo Wan; Gregory B Craven; Brad Hirakawa; Penney Khamphavong; Jeffrey R May; John C Kath; John D Lapek; Sherry Niessen; Alma L Burlingame; Jordan D Carelli; Jack Taunton
Journal:  Nat Chem Biol       Date:  2022-05-19       Impact factor: 16.174

3.  Covalent labeling of a chromatin reader domain using proximity-reactive cyclic peptides.

Authors:  Meng Yao Zhang; Hyunjun Yang; Gloria Ortiz; Michael J Trnka; Nektaria Petronikolou; Alma L Burlingame; William F DeGrado; Danica Galonić Fujimori
Journal:  Chem Sci       Date:  2022-05-12       Impact factor: 9.969

Review 4.  Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2.

Authors:  Vikram Choudhary; Amisha Gupta; Rajesh Sharma; Hamendra Singh Parmar
Journal:  J Proteins Proteom       Date:  2021-09-15

Review 5.  Advances in covalent drug discovery.

Authors:  Lydia Boike; Nathaniel J Henning; Daniel K Nomura
Journal:  Nat Rev Drug Discov       Date:  2022-08-25       Impact factor: 112.288

Review 6.  Recent advances in activity-based probes (ABPs) and affinity-based probes (AfBPs) for profiling of enzymes.

Authors:  Haixiao Fang; Bo Peng; Sing Yee Ong; Qiong Wu; Lin Li; Shao Q Yao
Journal:  Chem Sci       Date:  2021-05-18       Impact factor: 9.825

7.  Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2.

Authors:  Qizhang Li; Zhiying Wang; Qiang Zheng; Sen Liu
Journal:  Comput Struct Biotechnol J       Date:  2020-08-26       Impact factor: 7.271

8.  Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.

Authors:  Tihomir Tomašič; Martina Durcik; Bradley M Keegan; Darja Gramec Skledar; Živa Zajec; Brian S J Blagg; Sharon D Bryant
Journal:  Int J Mol Sci       Date:  2020-09-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.